Biocorrx Inc. (BICX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Biocorrx Inc. (BICX) stock forecast summary
On Oct. 16, 2026, BICX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
Biocorrx Inc. is a small-cap company with a market capitalization of $7M.
For BICX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -14.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BICX included.
Follow BICX freeBICX price chart and AI forecast
How BICX ranks among 5184 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Biocorrx Inc. (BICX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Specialty Outpatient Facilities, NEC peers listed below that report each metric.
Valuation & Market
| Metric | BICX | Rank |
|---|---|---|
| Market Cap | $7M | – |
| EPS | $-0.15 | – |
| Revenue/Share | $0.03 | – |
Profitability & Margins
| Metric | BICX | Rank |
|---|---|---|
| ROA | -165.7% | – |
| ROIC | 70.5% | – |
| Gross Margin | 34.6% | – |
| Operating Margin | -623.1% | – |
| Net Margin | -401.9% | – |
| EBT Margin | -399.4% | – |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | BICX | Rank |
|---|---|---|
| Current Ratio | 0.07x | – |
| Quick Ratio | 0.07x | – |
| Interest Coverage | -48.8x | – |
| Working Capital | -$8M | – |
Cash Flow
| Metric | BICX | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | – |
Operational Efficiency
| Metric | BICX | Rank |
|---|---|---|
| Asset Turnover | 0.41x | – |
| Receivables Turnover | 11.6x | – |
| Inventory Turnover | 3.3x | – |
| Days Sales Outstanding | 31 days | – |
| Days Inventory | 111 days | – |
| Payables Period | 11308 days | – |
| Cash Conversion Cycle | -11166 days | – |
Income Statement
| Metric | BICX | Rank |
|---|---|---|
| Total Revenue | $790K | – |
| Operating Income | -$5M | – |
| Net Income | -$3M | – |
| R&D Expense | $2M | – |
| SG&A Expense | $3M | – |
| Cost of Goods Sold | $140K | – |
Dividend & Shareholder Information
| Metric | BICX | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $620K | 32.6% of assets |
| Cash & Short-term Investments | $20K | 1.1% of assets |
| Accounts Receivable | $70K | 3.7% of assets |
| Inventory | $40K | 2.1% of assets |
| Total Liabilities | $14M | |
| Short-term Debt | $4M |
BICX quarterly financials and insider trading
Biocorrx Inc. (BICX) industry peers
Companies classified under the same SEC industry code as Biocorrx Inc. (Services-Specialty Outpatient Facilities, NEC): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere BICX sits on the market map
Biocorrx Inc. (BICX) stock news
Loading...
Biocorrx Inc. (BICX) stock forecast FAQ
What is the Biocorrx Inc. (BICX) stock forecast?
On Oct. 16, 2026, BICX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5184 stocks scored that day.
How accurate are Biocorrx Inc. stock predictions?
For BICX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -14.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Biocorrx Inc. forecasts updated?
Biocorrx Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Biocorrx Inc.'s industry peers?
4 issuers in our coverage, BICX included, share the SEC industry code Services-Specialty Outpatient Facilities, NEC. The largest are: Concentra Group Holdings Parent, Inc. (CON), Acadia Healthcare Company, Inc. (ACHC), Elite Health Systems Inc. (EHSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.